SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    World Health Organization Collaborating Center for Oral Precancerous Lesions. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol. 1978; 46: 518539.
  • 2
    Axell T, Pindborg JJ, Smith CJ, van der Waal I. Oral white lesions with special reference to precancerous and tobacco related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18–21, 1994. International Collaboration Group on Oral White Lesions. J Oral Pathol Med. 1996; 25: 4954.
  • 3
    Silverman S Jr., Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer. 1984; 53: 563568.
  • 4
    Pindborg JJ, Jolst O, Renstrup G, Roed-Petersen B. Studies on oral leukoplakia: a preliminary report on the period prevalence of malignant transformation in leukoplakia based on a follow-up study of 248 patients. J Am Dent Assoc. 1968; 76: 767771.
  • 5
    Silverman S, Gorsky M, Lozada-Nur F. A prospective follow-up study of 570 patients with oral lichen planus: persistence, remission and malignant association. Oral Surg Oral Med Oral Pathol. 1985; 60: 3034.
  • 6
    Eisenberg E. Oral lichen planus: a benign lesion. J Oral Maxillofac Surg. 2000; 58: 12781285.
  • 7
    Krutchkoff DJ, Eisenberg E. Lichenoid dysplasia: a distinct histopathologic entity. Oral Surg Oral Med Oral Pathol. 1985; 30: 308315.
  • 8
    Krutchkoff DJ, Cutler L, Laskowski S. Oral lichen planus: the evidence regarding potential malignant transformation. J Oral Pathol. 1978; 7: 17.
  • 9
    Urbizo-Velez J, Perez IR, Fenske, WA. Comparative histopathological studies in oral lichen planus. Acta Morphol Hungarica. 1990; 38: 7181.
  • 10
    Silverman S. Oral lichen planus: a potentially premalignant lesion. J Oral Maxillofac Surg. 2000; 58: 12861288.
  • 11
    Silverman S, Gorsky M, Lozada-Nur F, Giannotti K. A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol. 1991; 72: 665670.
  • 12
    Barnard NA, Scully C, Eveson JW, Cunningham S, Porter SR. Oral cancer development in patients with oral lichen planus. J Oral Pathol Med. 1993; 22: 421424.
  • 13
    Silverman S Jr., Bahl S. Oral lichen planus update: clinical characteristics, treatment responses, and malignant transformation. Am J Dent. 1997; 10: 259263.
  • 14
    Zhang L, Poh CF, Lam WL, et al. Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: molecular evidence of incomplete resection. Oral Oncol. 2001; 37: 505-12.
  • 15
    Zhang L, Cheung KJ Jr., Lam WL, et al. Increased genetic damage in oral leukoplakia from high risk sites: potential impact on staging and clinical management. Cancer. 2001; 91: 21482155.
  • 16
    Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low grade oral epithelial dysplasia. Clin Cancer Res. 2000; 6: 357362.
  • 17
    Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosome 3p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med. 1996; 2: 682685.
  • 18
    Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N Engl J Med. 2001; 344: 13231326.
  • 19
    Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001; 345: 1890900.
  • 20
    Chu FWK, Silverman S Jr., Dedo HH. CO2 laser treatment of oral leukoplakia. Laryngoscope. 1988; 98: 125130.
  • 21
    Vedtofte P, Holmstrup P, Hjorting-Hansen E, Pindborg JJ. Surgical treatment of premalignant lesions of the oral mucosa. Int J Oral Maxillofac Surg. 1987; 16: 656664.
  • 22
    Chiesa F, Boracchi P, Tradati N, et al. Risk of preneoplastic and neoplastic events in operated oral leukoplakias. Eur J Cancer B Oral Oncol. 1993; 29: 2328.
  • 23
    Einhorn J, Wersall J. Incidence of oral carcinoma in patients with leukoplakia of the oral mucosa. Cancer. 1967; 20: 21892193.
  • 24
    Epstein JB, Gorsky M, Wong FLW, Millner A. Topical bleomycin for the treatment of dysplastic oral leukoplakia. Cancer. 1998; 83: 629634.
  • 25
    Epstein JB, Gorsky M. Topical application of vitamin A to oral leukoplakia, a clinical case series. Cancer. 1999; 86: 921927.
  • 26
    Silverman S Jr., Eisenberg E, Renstrup G. A study of the effect of high doses of vitamin A on oral leukoplakia (hyperkeratosis) including toxicity, liver function and skeletal metabolism. J Oral Therapeut Pharmacol. 1965; 2: 923.
  • 27
    Koch HF. Biochemical treatment of precancerous oral lesions: the effectiveness of various analogues of retinoic acid. J Maxillofac Surg. 1978; 6: 5963.
  • 28
    Gudas LJ. Retinoids, retinoid-responsive genes, cell differentiation, and cancer. Cell Growth Diff. 1992; 3: 655662.
  • 29
    Hong WK, Lippman SM, Hittelman WN, Lotan R. Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Clin Cancer Res. 1995; 1: 677686.
  • 30
    Scher RL, Saito W, Dodge RK, Richtsmeier WJ, Fine RF. Fenretinide-induced apoptosis of human head and neck squamous carcinoma cell lines. Otolaryngol Head Neck Surg. 1998; 118: 464471.
  • 31
    Amos B, Lotan R. Retinoid sensitive cells and cells line. Methods Enzymol. 1991; 190: 217225.
  • 32
    Gaby SK, Bendich A. Vitamin A. In: GabySK, BendichA, SinghVN, MachlinLJ, editors. Vitamin intake and health. New York: Marcel Dekker, 1991: 1727.
  • 33
    DeVita VT Jr., Hellman S, Rosenberg SA. Cancer: principles and practice of oncology, 3rd ed. Philadelphia: JB Lippincott, 1989: 167180.
  • 34
    Zheng W, Blot WJ, Diamond EL, et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Res. 1993: 53: 795798.
  • 35
    Bollag W, Holdener EE. Retinoids in cancer prevention and therapy. Ann Oncol. 1992: 3: 513526.
  • 36
    Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990; 323: 795801.
  • 37
    Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst. 1994; 86: 140141.
  • 38
    Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med. 1995; 332: 14051410.
  • 39
    Lippman SM, Shin DM, Lee JJ, et al. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res. 1995; 55: 1619.
  • 40
    Shin DM, Xu XC, Lippman SM, et al. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clinical Cancer Res. 1997; 3: 875880.
  • 41
    Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 1994; 54: 31533159.
  • 42
    Giguere V, Ong ES, Segui P, Evans RM. Identification of a receptor for the morphogen retinoic acid. Nature. 1987; 330: 624629.
  • 43
    Copper MP, Klaassen I, Brakenhoff RH, Cloos J, Snow GB, Braakhuis BJ. All-trans retinoic acid induced gene expression and growth inhibition in head and neck cancer cell lines. Oral Oncol. 1997; 33: 270274.
  • 44
    Lippman SM, Hong WK. Chemoprevention of aerodigestive epithelial cancers. In: NewellGR, HongWK, editors. The biology and prevention of aerodigestive tract cancers. New York: Plenum Press, 1992: 151161.
  • 45
    Beenken SW, Sellers MT, Huang P, et al. Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid. Head Neck. 1999; 21: 566573.
  • 46
    Grandis JR, Zeng Q, Tweardy DJ. Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines. Nat Med. 1996; 2: 237240.
  • 47
    Oridate N, Lotan D, Xu XC, Hong WK, Lotan R. Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res. 1996; 2: 855863.
  • 48
    Eicher SA, Lotan R. Differential effects of retinoic acid and N-(4-hydroxyphenyl) retinamide on human head and neck squamous cell carcinoma cells. Laryngoscope. 1996; 106: 14711475.
  • 49
    Dowlatshali K, Metha RG, Thomas CF, Dingr NM, Moon RC. Therapeutic effect of N-(4-hydroxyphenyl) retinamide on N-methl-N-nitrosourea-induced rat mammary cancer. Cancer Lett. 1989; 47: 187192.
  • 50
    Chiesa F, Tradati N, Marazza M, et al. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Eur J Cancer B Oral Oncol. 1992; 28B: 97102.
  • 51
    Clifford JL, Sabichi AL, Zou C, et al. Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. Cancer Epidemiol Biomarkers Prevent. 2001; 10: 391395.
  • 52
    Sun SY, Li W, Yue P, Lippman SM, Hong WK, Lotan R. Mediation of N-4-hydroxyphenyl)retinimade-induced apoptosis in human cancer cells by different mechanisms. Cancer Res. 1999; 59: 24932498.
  • 53
    Lotan R. Roles of retinoids and their nuclear receptors in the development and prevention of upper aerodigestive tract cancer. Environ Health Perspect. 1997; 105 (Suppl 4): 985988.
  • 54
    Piattelli A, Fioroni M, Santinelli A, Rubini C. Bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study. Oral Oncol. 1999; 35: 314320.
  • 55
    Hong WK, Endicott J, Itri LM, et al. 13-Cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986; 315: 15011505.
  • 56
    Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med. 1993; 328: 1520.
  • 57
    Hays G, Lippman S, Toth B, et al. Evaluation of a synthetic analog of vitamin A and beta carotene on the clinical and biologic markers in human premalignant oral lesions. Oral Surg Oral Med Oral Pathol. 1991; 72: 311.
  • 58
    Shin DM, Mao L, Papdimitrakopoulou VM, et al. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst. 2000; 92: 6973.
  • 59
    Papdimitrakopoulou VM, Clayman G, Shin DM, et al. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg. 1999; 125: 1083-9.
  • 60
    Leuing A, Betz CS, Baumgartner R, Grevers G, Issing WJ. Initial experience in the treatment of oral leukoplakia with high-dose vitamin A and follow up 5-aminolevulinic acid induced protoporphyrin IX fluorescence. Eur Arch Otorhinolaryngol. 2000; 257: 327331.
  • 61
    Mathew B, Sankaranarayanan R, Nair PP, et al. Evaluation of chemoprevention of oral cancer with Spirulina fusiformis. Nutr Cancer. 1995; 24: 197202.
  • 62
    Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncol. 1997; 33: 231236.
  • 63
    Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett. 1988; 40: 93101.
  • 64
    Silverman S Jr., Renstrup G, Pindborg JJ. Studies in oral leukoplakias: III. Effects of vitamin A comparing clinical, histopathologic, cytologic and hematologic responses. Acta Odontol Scand. 1963; 21: 271292.
  • 65
    Kaugars G, Silverman S. The use of 13-cis-retinoic acid in the treatment of oral leukoplakia: short-term observations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995; 79: 264265.
  • 66
    Lippman SM, Kessler JF, Meyskens FL. Retinoids as preventive and therapeutic anticancer agents (Part II). Cancer Treat Rep. 1987; 71: 493515.
  • 67
    Koch HF. Biochemical treatment of precancerous oral lesions: the effectiveness of various analogues of retinoic acid. J Oral Maxillofac Surg. 1978; 6: 5963.
  • 68
    Gorsky M. Raviv M. Efficacy of etretinate (Tigason) in symptomatic oral lichen planus. Oral Surg Oral Med Oral Pathol. 1992; 73: 55-5.
  • 69
    Lippman SM, Meyskens FL Jr. Vitamin A derivatives in the prevention and treatment of human cancer. J Am Coll Nutr. 1988; 7: 269284.
  • 70
    Sloberg K, Hersle K, Mobacken H, Thilander H. Topical tretinoin therapy and oral lichen planus. Arch Dermatol. 1979; 115: 716718.
  • 71
    Giustina TA, Stewart JC, Ellis CN, Regezi JA. Annesley T, Woo TY, Voorhees JJ. Topical application of isotretinoin gel improves oral lichen planus. A double-blind study. Arch Dermatol. 1986; 122: 534536.
  • 72
    Shah JP, Strong EW, DeCosse JJ, Itri L, Sellers P. Effects of retinoids on oral leukoplakia. Am J Surg. 1983; 146: 466470.s
  • 73
    Tete S, Pappalardo S, Rubini C, Salini L, Falco A, Perfetti EG. The role of apoptosis and bcl-2 protein in topical treatment of oral leukoplakia with isotretinoin. Minerva Stomatol. 1999; 48: 411418.
  • 74
    van der Waal I, Schepman KP, van der Meij EH. A modified classification and staging system for oral leukoplakia. Oral Oncol. 2000; 36: 264266.
  • 75
    Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Prevalence study of oral white lesions with special reference to a new definition of oral leukoplakia. Eur J Cancer B Oral Oncol. 1996; 32B: 416419.